Your browser doesn't support javascript.
loading
Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults.
Florea, Ana; Sy, Lina S; Qian, Lei; Ackerson, Bradley K; Luo, Yi; Tubert, Julia E; Lee, Gina S; Ku, Jennifer H; Bruxvoort, Katia J; Talarico, Carla A; Qiu, Sijia; Tian, Yun; Tseng, Hung Fu.
Afiliación
  • Florea A; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Sy LS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Qian L; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Ackerson BK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Luo Y; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Tubert JE; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Lee GS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Ku JH; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Bruxvoort KJ; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Talarico CA; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Qiu S; Infectious Disease, Clinical Development, Moderna, Inc, Cambridge, Massachusetts, USA.
  • Tian Y; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
  • Tseng HF; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Clin Infect Dis ; 76(2): 252-262, 2023 01 13.
Article en En | MEDLINE | ID: mdl-36134518
BACKGROUND: We conducted a prospective cohort study at Kaiser Permanente Southern California to evaluate the relative vaccine effectiveness (rVE) of a booster dose vs 2-dose primary series of messenger RNA (mRNA)-1273 in immunocompetent individuals. METHODS: Immunocompetent adults who received a booster dose of mRNA-1273 from October 2021 through December 2021 were matched 1:1 to randomly selected 2-dose mRNA-1273 recipients by age, sex, race/ethnicity, and second-dose date and followed up through January 2022. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs), comparing outcomes (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection and coronavirus disease 2019 [COVID-19] hospitalization and hospital death) in the booster-dose and 2-dose groups. Adjusted rVE (%) was calculated as (1 - aHR) × 100. aHRs and rVE were also estimated by subgroup and month of follow-up. RESULTS: The study included 431 328 booster-dose vaccinated adults matched to 431 328 2-dose vaccinated adults. rVE was 61.3% (95% CI: 60.5%-62.2%) against SARS-CoV-2 infection, 89.0% (86.2%-91.2%) against COVID-19 hospitalization, and 96.0% (68.0%-99.5%) against COVID-19 hospital death. rVE against SARS-CoV-2 infection ranged from 55.6% to 66.7% across all subgroups. rVE against SARS-CoV-2 infection decreased from 67.1% (0 to <1 month of follow-up) to 30.5% (2 to <3 months). For COVID-19 hospitalization, rVE decreased from 91.2% (0 to <1 month) to 78.7% (2 to <3 months). CONCLUSIONS: Among immunocompetent adults, the mRNA-1273 booster conferred additional protection against SARS-CoV-2 infection and severe COVID-19 disease compared with the 2-dose mRNA-1273 primary series during periods of Delta and Omicron predominance.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Vacuna nCoV-2019 mRNA-1273 Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Vacuna nCoV-2019 mRNA-1273 Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos